schematic description of relevant issues of event rates, costs and outcomes of acute coronary syndrome (ACS) impacting income and fical outcomes.

1. ACUTE
CORONARY
SYNDROME
(ACS) COST-
BENEFIT
DYNAMICS:
ROHAN MCCLYMONT
2014

2. ACUTE CORONARY SYNDROME (ACS) COST-
BENEFIT DYNAMICS: MANAGEMENT DYNAMICS
PATIENT
DYNAMICS:
UA/NSTEMI/STE
MI
INTERVENTION
DYNAMICS: ONSET,
EFFICACY, SAFETY,
COST-EFFECTIVENESS
HOSPITALIZATION
DYNAMICS: COSTS
PER EVENT,
INTERVENTION
AVAILABILITY/CHOIC
E
OUTCOME DYNAMICS:
NEW CASES;RECURRENT
CASES ON MEDS; TOTAL
EVENT RATES

3. ACUTE CORONARY SYNDROME (ACS) COST-BENEFIT
DYNAMICS:
ACS MANAGEMENT COST-BENEFIT CONSIDERATIONS
HOSPITALIZATION
COSTS: ERD, WARD,
CATH LAB, THEATRE
(COST
VOLUME/EVENT?)
PHARMACOTHERAPY
COSTS: ERD, WARD,
THEATRE, CATH LAB,
CLINIC (COST
VOLUME/EVENT?)
PHARMACOTHERAPY
COSTS AND
HOSPITALIZATION COSTS
DUE TO TREATMENT
LIMITATIONS/FAILURES
COST OF USING
ONE INTERVENTION
OVER ANOTHER
(GREATER OR LESS?)
COST VERSUS
BENEFIT (GREATER
QUALITY OF LIFE AT
HIGHER PRICE, OR
OPTION 1 VERSUS
OPTION 2
(BRANDED OR
GENERIC) = LOWER
OR HIGHER EVENT
RATES? COST-
BENEFITS
CONSIDERATIONS?

4. ACUTE CORONARY SYNDROME (ACS) COST-BENEFIT DYNAMICS:
CLINICAL OUTCOMES AFFECT FISCAL OUTCOMES
 COSTS OF INTERVENTIONS ARE COMPOUNDED WITH EACH CLINICAL EVENT:
 ASSOCIATED COSTS PER EVENT IMPACT THE INCOME BUDGETED
 ESP. REPEAT PATIENTS, CLINICAL EVOLUTION WHILE ON SUBOPTIMAL THERAPY
 INTERVENTIONS IMPACT CLINICAL OUTCOMES AND FISCAL DEMAND:
 COST-BENEFITS OF ONE OPTION VERSUS ANOTHER, SINCE OUTCOMES
COMPOUND COSTS
 EVIDENCE-BASED INTERVENTIONS IMPACT FISCAL OUTCOMES:
 (LESS SPENT FROM BUDGETS/COLLECTIONS – HIGHER MARGINS, MORE FUNDS
RETURNED, EXCESS SPENDING PREVENTED)
 INTERVENTIONS IMPACT BOTH CLINICAL AND FISCAL OUTCOMES:
 POSSIBLE TO SAVE LIVES AND MONEY